Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, talks about how education of patients is so important, the upcoming parts of the AAD guidelines to look forward to, and more.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research expands on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is held from April 9 to 11 in Baltimore, Maryland.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, discusses the American Academy of Dermatology's approach to atopic dermatitis management.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the importance of recognizing children with more severe atopic disease and a team approach to treatment.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, explores the hidden burdens of itch that many pediatric patients and parents have to deal with on a daily basis. She expanded on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference was held from April 9 to 11 in Baltimore, Maryland

What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research dives into the importance of the results from their recently released study.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.

Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.

An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.

Terri Phillips, MD, FAAP, expands on her letter to the editor in the April issue of Dermatology Times® diving into how her experience has shaped the her view of the aesthetics industry, the challenges both physicians and patients face, and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc attended the 2022 American Academy of Dermatology (AAD) Annual Meeting and talked to several dermatologists about skin care and common misconceptions about this topic.

What are the best post- and pre-lightening products and strategies for optimal results on all skin types? Renata Block, president of the Society of Dermatology Physician Assistants, walked through her pearls in this interview at the American Academy of Dermatology 2022 Annual Meeting.

Renata Block, MMS, PA-C, president of the Society of Dermatology Physician Assistants (PAs) talked with Dermatology Times® at the American Academy of Dermatology 2022 Annual Meeting about the broadening opportunities for these advanced health care providers to help fill the demand gap for treatment of skin and hair disorders as well as aesthetic services.

In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.

VisualDX uses diverse imagery to help increase knowledge of disease manifestations in a range of skin types.

In this fourth part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, talks about what to look forward to in treatment and clinical trials of merkel cell carcinoma (MCC).

In this third part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, highlights the in practice experiences in using circulating tumor DNA for merkel cell carcinoma (MCC).

Dr Andrew Blauvelt reviews key highlights and clinical implications from the LIBERTY AD OLE study assessing the effect of long-term dupilumab treatment on efficacy improvements in adults with moderate to severe atopic dermatitis.

Andrew Blauvelt, MD, MBA, reviews recent advances in the therapeutic landscape for moderate to severe atopic dermatitis.